Characteristicsof patients with acquired del(17p) at MM diagnosisand at detection of del(17p), and control patients at MM diagnosis
| Characteristic . | No. of patients with available data in the 3 groups . | Acquired del(17p) at MM diagnosis (n = 76) . | Control group at MM diagnosis (n = 152) . | Acquired del(17p) at detection of del(17p) (n = 76) . | P* for acquired del(17p) vs controls at MM diagnosis . |
|---|---|---|---|---|---|
| Age, y | |||||
| Median (range) | 61.9 (42.4-80.9) | 61.4 (28.8-84.7) | 65.6 (44.6-82.2) | .972 | |
| ≥65, n (%) | 28 (36.8) | 51 (33.5) | 39 (51.3) | .659 | |
| Female sex, n (%) | 30 (39.5) | 63 (41.4) | 30 (39.5) | .886 | |
| Median hemoglobin (range), g/dL | 69/150/75 | 10.8 (5.4-14.5) | 11.3 (7.1-16.7) | 10.4 (7.2-14.7) | .035 |
| Median calcium (range), mg/dL | 60/146/73 | 9.6 (7.2-15.4) | 9.6 (7.9-15) | 9.5 (7.1-11.5) | .598 |
| Creatinine >2 mg/dL, n (%) | 64/145/74 | 8 (12.5) | 10 (6.9) | 4 (5.4) | .191 |
| Median bone marrow plasma cell percentage (range) | 70/150/75 | 40 (4-93) | 50 (3-98) | 40 (2-100) | .384 |
| High plasma cell proliferative rate, n (%) | 45/106/65 | 14 (31.1) | 22 (20.7) | 32 (49.2) | .211 |
| Median percentage of plasma cells with del(17p) (range) | —/—/71 | — | — | 89 (9-100) | |
| Median M-protein level (range), g/dL | 65/146/74 | 2.8 (0-12.3) | 2.7 (0-6.8) | 1.8 (0-6.4) | .999 |
| M-protein isotype, n (%) | 76/152/76 | ||||
| IgG | 46 (60.5) | 88 (57.9) | 46 (60.5) | .097 | |
| IgA | 21 (27.6) | 36 (23.7) | 21 (27.6) | ||
| Light chain | 5 (6.6) | 25 (16.4) | 5 (6.6) | ||
| Others | 4 (5.3) | 3 (2.0) | 4 (5.3) | ||
| ISS I/II vs III, n (%) | 56/136/56 | 42 (75.0)/ 14 (25.0) | 110 (80.9)/ 26 (19.1) | 43 (76.8)/ 13 (23.2) | .434 |
| Increased LDH, n (%) | 51/121/61 | 7 (13.7) | 5 (4.1) | 21 (33.4) | .043 |
| Cytogenetic abnormalities at MM diagnosis for cases and controls and at acquisition of del (17p), n (%) | |||||
| High-risk chromosomal translocation | 14 (18.4) | 14 (9.2) | 14 (18.4) | .055 | |
| t(4;14) | 12 (15.8) | 10 (6.6) | 12 (15.8) | .033 | |
| t(6;14)† | 0 (0) | 0 (0) | 0 (0) | — | |
| t(11;14) | 15 (19.7) | 37 (24.3) | 15 (19.7) | .505 | |
| t(14;16) | 2 (2.6) | 3 (2.0) | 2 (2.6) | 1.000 | |
| t(14;20)† | 0 (0) | 1 (1.4) | 0 (0) | 1.000 | |
| Hyperdiploidy (trisomy or tetrasomy involving ≥2 odd-numbered chromosomes) | 32 (42.1) | 69 (45.4) | 41 (53.9) | .673 | |
| del(13q) and/or monosomy 13 | 30 (39.5) | 67 (44.1) | 45 (59.2) | .570 | |
| del(13q) | 3 (3.9) | 8 (5.3) | 5 (6.6) | .756 | |
| Monosomy 13 | 27 (35.5) | 59 (38.8) | 41 (53.9) | .666 | |
| (1q22) gain‡ | 0 (0) | 1 (12.5) | 4 (28.6) | 1.000 | |
| del(1p32)‡ | 0 (0) | 0 (0) | 0 (0) | — |
| Characteristic . | No. of patients with available data in the 3 groups . | Acquired del(17p) at MM diagnosis (n = 76) . | Control group at MM diagnosis (n = 152) . | Acquired del(17p) at detection of del(17p) (n = 76) . | P* for acquired del(17p) vs controls at MM diagnosis . |
|---|---|---|---|---|---|
| Age, y | |||||
| Median (range) | 61.9 (42.4-80.9) | 61.4 (28.8-84.7) | 65.6 (44.6-82.2) | .972 | |
| ≥65, n (%) | 28 (36.8) | 51 (33.5) | 39 (51.3) | .659 | |
| Female sex, n (%) | 30 (39.5) | 63 (41.4) | 30 (39.5) | .886 | |
| Median hemoglobin (range), g/dL | 69/150/75 | 10.8 (5.4-14.5) | 11.3 (7.1-16.7) | 10.4 (7.2-14.7) | .035 |
| Median calcium (range), mg/dL | 60/146/73 | 9.6 (7.2-15.4) | 9.6 (7.9-15) | 9.5 (7.1-11.5) | .598 |
| Creatinine >2 mg/dL, n (%) | 64/145/74 | 8 (12.5) | 10 (6.9) | 4 (5.4) | .191 |
| Median bone marrow plasma cell percentage (range) | 70/150/75 | 40 (4-93) | 50 (3-98) | 40 (2-100) | .384 |
| High plasma cell proliferative rate, n (%) | 45/106/65 | 14 (31.1) | 22 (20.7) | 32 (49.2) | .211 |
| Median percentage of plasma cells with del(17p) (range) | —/—/71 | — | — | 89 (9-100) | |
| Median M-protein level (range), g/dL | 65/146/74 | 2.8 (0-12.3) | 2.7 (0-6.8) | 1.8 (0-6.4) | .999 |
| M-protein isotype, n (%) | 76/152/76 | ||||
| IgG | 46 (60.5) | 88 (57.9) | 46 (60.5) | .097 | |
| IgA | 21 (27.6) | 36 (23.7) | 21 (27.6) | ||
| Light chain | 5 (6.6) | 25 (16.4) | 5 (6.6) | ||
| Others | 4 (5.3) | 3 (2.0) | 4 (5.3) | ||
| ISS I/II vs III, n (%) | 56/136/56 | 42 (75.0)/ 14 (25.0) | 110 (80.9)/ 26 (19.1) | 43 (76.8)/ 13 (23.2) | .434 |
| Increased LDH, n (%) | 51/121/61 | 7 (13.7) | 5 (4.1) | 21 (33.4) | .043 |
| Cytogenetic abnormalities at MM diagnosis for cases and controls and at acquisition of del (17p), n (%) | |||||
| High-risk chromosomal translocation | 14 (18.4) | 14 (9.2) | 14 (18.4) | .055 | |
| t(4;14) | 12 (15.8) | 10 (6.6) | 12 (15.8) | .033 | |
| t(6;14)† | 0 (0) | 0 (0) | 0 (0) | — | |
| t(11;14) | 15 (19.7) | 37 (24.3) | 15 (19.7) | .505 | |
| t(14;16) | 2 (2.6) | 3 (2.0) | 2 (2.6) | 1.000 | |
| t(14;20)† | 0 (0) | 1 (1.4) | 0 (0) | 1.000 | |
| Hyperdiploidy (trisomy or tetrasomy involving ≥2 odd-numbered chromosomes) | 32 (42.1) | 69 (45.4) | 41 (53.9) | .673 | |
| del(13q) and/or monosomy 13 | 30 (39.5) | 67 (44.1) | 45 (59.2) | .570 | |
| del(13q) | 3 (3.9) | 8 (5.3) | 5 (6.6) | .756 | |
| Monosomy 13 | 27 (35.5) | 59 (38.8) | 41 (53.9) | .666 | |
| (1q22) gain‡ | 0 (0) | 1 (12.5) | 4 (28.6) | 1.000 | |
| del(1p32)‡ | 0 (0) | 0 (0) | 0 (0) | — |
IgA, immunoglobulin A; IgG, immunoglobulin G.
P for Mann-Whitney U test for continuous variables and Fisher’s exact test for categorical variables.
Calculation is limited to cases and controls who had FISH testing after May 2009 (n = 37 for cases at diagnosis, n = 69 for controls at diagnosis, and n = 68 for cases at del(17p) detection) when probes for these abnormalities were introduced.
Calculation limited to cases and controls who had FISH testing after August 2014 (n = 4 for cases at diagnosis, n = 8 for controls at diagnosis, and n = 14 for cases at del(17p) detection) when probes for 1q gain and del(1p) were introduced.